MOL 4239

Drug Profile

MOL 4239

Alternative Names: MOL4239; WP 1220

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Dermin; Moleculin; Moleculin Biotech
  • Class Antipsoriatics; Cinnamates; Small molecules
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cutaneous T cell lymphoma
  • Discontinued Plaque psoriasis

Most Recent Events

  • 13 Sep 2017 Moleculin intends to file an IND application for Cutaneous T-Cell Lymphoma in Poland
  • 13 Sep 2017 Moleculin plans a proof-of-concept trial for Cutaneous T-Cell Lymphoma in Poland
  • 13 Jun 2017 Moleculin intends to file an IND application with the US FDA for Cutaneous T-Cell Lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top